Innogenetics and Solvay Pharmaceuticals extend collaboration for biomarker discovery
10-Apr-2008
Solvay and Innogenetics have now confirmed their intention to extend the research program for another 2 years until December 2010. The program will explore potential biomarkers and develop diagnostic assays that could serve as companion diagnostic products for selected Solvay therapeutics programs. Furthermore, Innogenetics will retain rights for development of biomarkers for commercialization in diagnostic kits.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.